Abstract

Progressive impairment of insulin secretion in people with type 2 diabetes leads to blood glucose concentrations worsening over time, often resulting in escalation of blood glucose lowering therapy.¹ In 2015/2016, more money was spent on dipeptidyl peptidase-4 (DPP-4) inhibitors (‘gliptins’) than on any other class of antidiabetic drug except for insulins.² In 2008, we reviewed sitagliptin and vildagliptin.³ Here, we briefly review three other DPP-4 inhibitors, saxagliptin (Onglyza—AstraZeneca), linagliptin (Trajenta—Boehringer Ingelheim) and ▼alogliptin (Vipidia—Takeda), and consider data from recent cardiovascular outcomes studies.